Yahoo Finance • 25 days ago
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrat... Full story
Yahoo Finance • last month
DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved... Full story
Yahoo Finance • last month
– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy i... Full story
Yahoo Finance • last month
– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fo... Full story
Yahoo Finance • last month
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the fol... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: Avadel Pharmaceuticals (AVDL) Q2 2025 MANAGEMENT VIEW * CEO Gregory J. Divis highlighted that "we are incredibly pleased with the results we achieved in the second quarter, including growing patient demand with... Full story
Yahoo Finance • 2 months ago
Avadel Pharmaceuticals (NASDAQ:AVDL [https://www.chartmill.com/stock/quote/AVDL]) reported second-quarter 2025 financial results that exceeded analyst expectations, driving a positive market reaction in pre-market trading. The company’s st... Full story
Yahoo Finance • 2 months ago
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live... Full story
Yahoo Finance • 3 months ago
Avadel Pharmaceuticals (NASDAQ:AVDL) is one of the most undervalued small-cap stocks to buy according to analysts. On June 30, Avadel Pharmaceuticals announced that the US Court of Appeals for the District of Columbia Circuit (Appeals Cour... Full story
Yahoo Finance • 3 months ago
Investing.com -- Avadel Pharmaceuticals PLC (NASDAQ:AVDL) stock rose 4.7% after a U.S. appeals court unanimously upheld the FDA’s approval of LUMRYZ, the company’s once-at-bedtime treatment for narcolepsy, in litigation brought by Jazz Ph... Full story
Yahoo Finance • 3 months ago
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals fo... Full story
Yahoo Finance • 3 months ago
Investing.com -- Investor ASL Strategic Value Fund plans to urge shareholders to vote against Avadel Pharmaceuticals’ (NASDAQ:AVDL) entire board of directors, according to the The Wall Street Journal on Sunday. The investment firm intends... Full story
Yahoo Finance • 4 months ago
[asian woman sleepless at night] PonyWang/E+ via Getty Images * Avadel Pharmaceuticals (NASDAQ:AVDL [https://seekingalpha.com/symbol/AVDL]) said on Thursday that its sleep disorder medication, Lumryz, got U.S. FDA's Orphan Drug status f... Full story
Yahoo Finance • 4 months ago
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation... Full story
Yahoo Finance • 5 months ago
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodrigu... Full story
Yahoo Finance • 5 months ago
The U.S. Court of Appeals for the Federal Circuit reversed-in-part, vacated-in part and remanded a prior ruling from the United States District Court for the District of Delaware in No. 1:21-cv-01594-GBW, a suit between Avadel Pharmaceutic... Full story
Yahoo Finance • 5 months ago
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year ove... Full story
Yahoo Finance • 5 months ago
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narco... Full story
Yahoo Finance • 6 months ago
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Confer... Full story
Yahoo Finance • 6 months ago
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fire... Full story